Moleculin Biotech Q3 net loss narrows 74% to $6.49 million
MBRX•Moleculin Biotech’s third-quarter 2026 net loss narrowed 74% year over year to $6.49 million, while cash and cash equivalents totaled $7.29 million at September 30. Treatment was completed for all 90 patients in Part A of its pivotal MIRACLE trial.
1. Quarterly results and trial
Moleculin Biotech’s third-quarter 2026 net loss narrowed 74% year over year to $6.49 million. Research and development expenses rose 20% to $4.49 million, primarily due to MIRACLE clinical trial activities, and cash and cash equivalents totaled $7.29 million at September 30, 2026. Treatment finished for all 90 patients in Part A of the pivotal trial evaluating Annamycin for relapsed or refractory AML; comprehensive Part A data remain expected in Q1 2027, with Part B planned to begin in the first half of 2027.




